Dr. Joseph Krepp was awarded a research grant of $82,560 from Pfizer to study Transthyretin Cardiac Amyloidosis in Patients with Suspected Hypertensive Heart Disease. Cardiac Amyloidosis is an uncommon disease in which proteins can abnormally deposit into the heart muscle leading to thickening and stiffening of the heart, leading to heart failure. This disease has traditionally been underdiagnosed and confused with heart disease from hypertension. Using nuclear imaging techniques, cardiologists are now able to screen and identify cardiac amyloidosis at earlier disease stages.
The GW Division of Cardiology has established an Infiltrative Cardiomyopathy team led by Dr. Joseph Krepp and Dr. Gurusher Panjrath, who use cutting edge technologies and novel therapies to diagnose and treat patients with cardiac amyloidosis. This investigator initiated research grant will help our team to better target which patients have cardiac amyloidosis, leading to earlier identification and improved patient outcomes.
